Amgen Inc

NASDAQ:AMGNUnited States

Yesterday

Show headlines and story abstract

• DJ Amgen Gets FDA Approval for Small-Cell Lung-Cancer Treatment, from 7 hours ago by Dow Jones

  7 hours ago by Dow Jones
  Companies Mentioned: AMGN
  
  By Ben Glickman
  
  Amgen on Thursday received approval from U.S. regulators for its drug to treat a form of late-stage lung-cancer.
  
  The pharmaceutical company said that Imdelltra, an immunotherapy, was approved by the U.S. Food and Drug Administration for treating adults with extensive-stage small-cell lung cancer.
  

• FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER, from 7 hours ago by PR Newswire

  7 hours ago by PR Newswire
  Companies Mentioned: AMGN

  Breakthrough DLL3-Targeting TherapyRegimen for a Major Solid Tumor

  IMDELLTRA Demonstrated Impressive 40% Objective Response Rate, 9.7 Month Median Duration of Response and 14.3 Month Median Overall Survival in Pivotal DeLLphi-301 Study

• FDA APPROVES IMDELLTRA(TM) (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER, from 7 hours ago by Dow Jones

  7 hours ago by Dow Jones
  Companies Mentioned: AMGN
  
  new products. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.
  

• Amgen's Imdelltra Gets US FDA Accelerated Approval for Drug to Treat Extensive Stage Small Cell Lung Cancer, from 9 hours ago by MT Newswires

  9 hours ago by MT Newswires
  Companies Mentioned: AMGN
  04:16 PM EDT, 05/16/2024 (MT Newswires) -- Amgen's (AMGN) Imdelltra received accelerated approval from the US Food and Drug Administration for the treatment of patients with extensive stage small cell lung cancer whose tumors have stopped responding...

• DJ Roche's New Weight-Loss Data Shows Lilly Isn't Unbeatable in Obesity -- Barrons.com, from 15 hours ago by Dow Jones

  15 hours ago by Dow Jones
  Companies Mentioned: LLY, NVO, RHHBY, AMGN, VKTX
  
  By Josh Nathan-Kazis
  
  Roche unveiled impressive early-stage results in a small trial of a weight-loss drug called CT-388 that could make the company a serious player in the obesity-drug market in the coming years.